ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of GLA (5 mcg) on Human Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01864876
Recruitment Status : Completed
First Posted : May 30, 2013
Last Update Posted : February 26, 2014
Sponsor:
Collaborator:
Rockefeller University
Information provided by (Responsible Party):
IDRI

Brief Summary:
This protocol is for a phase 1, randomized, single-blinded study to evaluate the safety and tolerability of a single 5 mcg dose of GLA-SE administered intramuscularly and GLA-AF administered subcutaneously. The second focus will be to detail the global immune response by measuring systemic cytokines, chemokines, and global gene regulation. The third focus will be to investigate the effects of GLA on the peripheral blood immune cells including monocytes and dendritic cells. The results of this trial will generate supportive human data to use GLA as an adjuvant in a dendritic cell-targeted vaccine strategy.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Biological: GLA-AF Biological: GLA-SE Biological: EM060G (SE) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: A Randomized, Single-Blinded Phase 1 Study to Evaluate the Safety and Immunogenicity of a Single Administration of 5 mcg GLA in Healthy Volunteers
Study Start Date : September 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: GLA-AF
5 mcg GLA-AF given as one subcutaneous injection.
Biological: GLA-AF
Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).

Experimental: GLA-SE
5 mcg GLA-SE given as one intramuscular injection.
Biological: GLA-SE
Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).

Experimental: EM060G (SE)
EM060G (SE) given as one intramuscular injection.
Biological: EM060G (SE)
The same stable oil-in-water emulsion (SE), but without GLA.




Primary Outcome Measures :
  1. Safety [ Time Frame: 1 year ]

    Local reactogenicity events and systemic reactogenicity events will be monitored for 28 days post injection.

    • Local reactogenicity events include tenderness, erythema, skin discoloration, edema, vesicle formation or ulceration, induration, pruritus, formation of a crust or scab, or other.
    • Systemic reactogenicity events include fever, chills, headache, nausea, vomiting, malaise, myalgia, arthralgia, and rash.

    Long term safety will be monitored by follow-up phone calls at 3 months, 6 months, and 1 year post injection.



Secondary Outcome Measures :
  1. Immunogenicity [ Time Frame: 28 days ]
    Describe the global immune response by measuring systemic cytokines, chemokines and global gene regulation. Investigate the effects of GLA on the peripheral blood immune cells including monocytes and dendritic cells.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adult males and females, as assessed by a medical history, physical exam,and laboratory tests;
  2. Age of at least 18 years of age on the day of screening and no greater than 50 years at time of administration;
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 4 weeks);
  4. Willing to undergo HIV testing and counseling and receive HIV test results;
  5. If a female of child bearing potential, must be willing to use two effective methods of contraception (combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine Device (IUD); condoms; anatomical sterility in self or partner) until 6 weeks after study drug administration. If a sexually active male, must be willing to use two effective methods of contraception (such as condoms, anatomical sterility) from screening until 6 weeks after study drug administration (same as above) and will be advised not to get his partner(s) pregnant during this time.

Exclusion Criteria:

  1. Positive for hepatitis B surface antigen, positive for hepatitis C antibodies, or active syphilis infection based on clinical evaluation;
  2. Confirmed HIV-1 or HIV-2 infection;
  3. Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease;
  4. Any use of systemic corticosteroids immunosuppressive anticancer medications;
  5. Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation;
  6. Any laboratory value outside of reference range other than CRP, with the exception of any non-clinically significant Grade I elevations of liver function tests (AST, ALT, direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined by the Principal Investigator or his designee.
  7. Within the 12 months prior to enrollment, the subject self reports excessive daily alcohol use, frequent binge drinking or chronic marijuana abuse (defined as greater than 2 times a week) or any other use of illicit drugs;
  8. If female, pregnant, planning a pregnancy during the trial period, or lactating;
  9. Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days prior to study drug;
  10. Prior receipt of GLA in another research study;
  11. Participation in another clinical study of an investigational product currently or within past 16 weeks, or expected participation during this study;
  12. In the opinion of the investigator, unlikely to comply with protocol due to medical, social or psychiatric reasons;
  13. Allergy to eggs
  14. A glomerular filtration rate that is less than 60 mL/min/1.73 m2 as calculated by study team based on laboratory creatinine values.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01864876


Locations
United States, New York
Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
IDRI
Rockefeller University
Investigators
Study Director: Franco Piazza, MD, MPH IDRI

Responsible Party: IDRI
ClinicalTrials.gov Identifier: NCT01864876     History of Changes
Other Study ID Numbers: MCA-0784
First Posted: May 30, 2013    Key Record Dates
Last Update Posted: February 26, 2014
Last Verified: February 2014